(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
When faith comes under fire: How Iran’s repression of religious minorities has increased - 2Liste des pr\u00eats qui ne n\u00e9cessitent pas de remboursement
- 3The Way to Business: Startup Illustrations Learned
- 4The Way to Monetary Health: Individual budget Change
- 5Deadly attack on kindergarten reported in Sudan
- Choosing Moving Styles for Your Restroom Redesign
- Congolese rape survivors search in vain for medicine after USAID cuts
- Step by step instructions to Involve Compact disc Rates for Magnanimous Giving
- All that You Really want to Be aware of Dental Inserts Facilities
- Instructions to Investigate Different Open Record Extra Offers Actually
- 7 Odd Apparatuses to Make Your Party Stick Out!
- Material of Innovativeness: A Survey of \Releasing Your Imaginative Potential\ Online Workmanship Course
- Fundamental Home Machines for Improved Solace in Summer
- Aurora chaser catches a fox basking in the glow of Finland's legendary 'fox fires' (photos)
